Shri Narsimha Chemo Pharma.Ltd. Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 1.41 M
- Company Age 32 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth %
- Profit Growth -6.45%
- Ebitda -6.45%
- Net Worth -0.56%
- Total Assets
About Shri Narsimha Chemo Pharma.Ltd.
Shri Narsimha Chemo Pharma Pvt.Ltd. (SNCPP) is a Private Limited Indian Non-Government Company incorporated in India on 28 July 1992 and has a history of 32 years and six months. Its registered office is in Aurangabad, Maharashtra, India.
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.41 M, as per Ministry of Corporate Affairs (MCA) records.
Mahendra Borad, Rasik Patel, Jasu Patel, and One other member serve as directors at the Company.
Company Details
- Location
Aurangabad, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media-
Corporate Identity Details
- CIN/LLPIN
U24139MH1992PTC067916
- Company No.
067916
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
28 Jul 1992
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Shri Narsimha Chemo Pharma.Ltd.?
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mahendra Borad  | Whole-Time Director | 01-Jul-2005 | Current |
| Rasik Patel | Whole-Time Director | 01-Jun-2009 | Current |
| Jasu Patel | Whole-Time Director | 01-Jun-2009 | Current |
| Ankit Patel | Director | 15-Jun-2020 | Current |
Financial Performance of Shri Narsimha Chemo Pharma.Ltd..
Shri Narsimha Chemo Pharma Pvt.Ltd., for the financial year ended 2020, experienced no change in revenue, with a 0% increase. The company also saw a slight decrease in profitability, with a 6.45% decrease in profit. The company's net worth dipped by a decrease of 0.56%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Shri Narsimha Chemo Pharma.Ltd.?
Unlock access to Shri Narsimha Chemo Pharma.Ltd.'s control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Shri Narsimha Chemo Pharma.Ltd.?
Unlock and access historical data on people associated with Shri Narsimha Chemo Pharma.Ltd., such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Shri Narsimha Chemo Pharma.Ltd., offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Shri Narsimha Chemo Pharma.Ltd.'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
